By a News Reporter-Staff News Editor at Biotech Week -- Researchers detail new data in Ischemia. According to news reporting originating from Miyagi, Japan, by NewsRx correspondents, research stated, "The translation of experimental stroke research from the laboratory to successful clinical practice remains a formidable challenge. We previously reported that PEGylated-lipid nanoparticles (PLNs) effectively transport across the blood-brain barrier along with less inflammatory responses."
Our news editors obtained a quote from the research from Tohoku University, "In the present study, PLNs conjugated to Fas ligand antibody that selectively present on brain ischaemic region were used for therapeutic targeting. Fluorescent analysis of the mice brain show that encapsulated 3-n-Butylphthalide (dl-NBP) in PLNs conjugated with Fas ligand antibody effectively delivered to ipsilateral region of ischaemic brain. Furthermore, the confocal immunohistochemical study demonstrated that brain-targeted nanocontainers specifically accumulated on OX42 positive microglia cells in ischaemic region of mice model. Finally, dl-NBP encapsulated nano-drug delivery system is resulted in significant improvements in brain injury and in neurological deficit after ischaemia, with the significantly reduced dosages versus regular dl-NBP."
According to the news editors, the research concluded: "Overall, these data suggests that PLNs conjugated to an antibody specific to the Fas ligand constituted an ideal brain targeting drug delivery system for brain ischaemia."
For more information on this research see: Targeted therapy of brain ischaemia using Fas ligand antibody conjugated PEG-lipid nanoparticles. Biomaterials, 2014;35(1):530-537. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
The news editors report that additional information may be obtained by contacting Y.M. Lu, Tohoku University, Grad Sch Pharmaceut Sci, Dept. of Pharmacol, Sendai, Miyagi 9808574, Japan. Additional authors for this research include J.Y. Huang, H. Wang, X.F. Lou, M.H. Liao, L.J. Hong, R.R. Tao, M.M. Ahmed, C.L. Shan, X.L. Wang, K. Fukunaga, Y.Z. Du and F. Han (see also Ischemia).
Keywords for this news article include: Asia, Antibodies, Japan, Miyagi, Therapy, Ischemia, Angiology, Cardiology, Immunology, Nanoparticle, Blood Proteins, Nanotechnology, Immunoglobulins, Drug Delivery Systems, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC